Barrow Robert 4
4 · Definium Therapeutics, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Definium Therapeutics (DFTX) CEO Robert Barrow Sells 24,431 Shares
What Happened Robert Barrow, CEO of Definium Therapeutics (DFTX), reported the sale of 24,431 common shares on March 25, 2026. The weighted-average sale price was $18.47 per share, resulting in proceeds of approximately $451,241. This was a sale (not a purchase) carried out to satisfy tax withholding obligations related to vested restricted stock units.
Key Details
- Transaction date: March 25, 2026 (Form 4 filed March 26, 2026 — timely filing).
- Transaction type: Sale (sell-to-cover to satisfy tax withholding on vested RSUs) under a Rule 10b5-1 plan adopted June 15, 2022.
- Price: Weighted-average $18.47; individual sales ranged from $18.36 to $18.80. The filer will provide a breakdown of shares sold at each price on request.
- Shares sold: 24,431; proceeds ≈ $451,241.
- Shares owned after transaction: Not reported in this filing.
- Footnotes: F1 — sale to satisfy withholding on vested RSUs via sell-to-cover under a 10b5-1 plan; F2 — weighted-average price and range disclosure; F3 — form notes 1,586 shares were acquired under the 2024 Employee Share Purchase Plan.
Context This sale appears to be a routine sell-to-cover for tax withholding on vested RSUs rather than an open-market liquidation motivated by trading views. Such withholding sales are common and do not necessarily indicate the insider’s sentiment about the company’s prospects. Purchases by insiders generally carry more interpretive weight for bullish signals.
Insider Transaction Report
- Sale
Common Shares
[F1][F2][F3]2026-03-25$18.47/sh−24,431$451,241→ 752,454 total
Footnotes (3)
- [F1]Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022.
- [F2]The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.